HIGHLIGHTS
- who: Daniel Morgensztern from the Washington University of Medicine, Stanford, CA, USA have published the research: RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer, in the Journal: (JOURNAL) of 15/05/2019
- what: The authors report the initial cohort of patients with SCLC. The study was approved by the Institutional Review Board at each of the participating sites and conducted in accordance with the principles of good clinical practice and the declaration of Helsinki. The study showed that RRx-001 is well tolerated and associated with subsequent . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.